Please login to the form below
Medivation
This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Talzenna cleared for breast cancer in Europe
Talzenna was acquired by Pfizer as part of its $14bn takeover of Medivation in 2016, and earlier this month the company made another mid-range acquisition in cancer, agreeing to buy
Latest news
-
Pfizer adds Array to cancer arsenal with $11bn acquisition
The acquisition announced yesterday is the big pharma company's largest since it bought another oncology specialist, Medivation in 2016 for $14bn, and could help build a third cancer blockbuster franchise ... The 2016 Medivation buyout saw its value drop
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
rivals when trying to bolt on Medivation (which went to Pfizer) and Actelion (bought by Johnson &Johnson).
-
Pfizer names next CEO as Read retires
One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology
-
Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more
The company acquired the candidate when it bought out Medivation for $14bn in 2016, and needs to recoup its investment with a successful PARP competitor.
-
Sanofi sells European generics to Advent for $2.4bn
for Medivation and Actelion.
More from news
Approximately 15 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
The latter includes its $11.4bn deal to buy Array Biopharma – the biggest for the group since its $14.3bn takeover of cancer specialist Medivation – that added two marketed drugs (Mektovi
-
Deal Watch December 2016
Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.
-
Deal Watch August 2016
So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.
-
Deal Watch May 2016
on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC
-
Deal Watch April 2016
Sanofi would like to merge with Medivation as it makes “strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.
More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Revolution Medicines appoints Dr Stephen Kelsey
Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
-
Avanir Pharmaceuticals appoints new president and CEO
He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson &Johnson and Centocor.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
